Biodexa Pharmaceuticals

Edison Investment Research is terminating coverage on Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Weight-loss drugs – how are GLP-1s redistributing consumer spending?

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Biodexa Pharmaceuticals (NASDAQ: BDRX)

Latest Insights

Biodexa Pharmaceuticals — In a period of transition

Biodexa Pharmaceuticals — Foray into T1D expands business scope

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline

Market Data

Sector

Midatech Pharma — MTX110 receives ODD from the EMA for gliomas

Midatech Pharma — Interim DIPG data to be presented at ISPNO

Midatech Pharma — MTX110’s path to market fast-tracked in rGBM

Midatech Pharma — Pipeline delivery key to future outlook

Midatech Pharma: Edison Open House Healthcare 2022

Midatech Pharma — Q-Sphera partnership with Janssen expanded

Midatech Pharma — Pivoting its commercial strategy

Midatech Pharma – Edison Open House interview